Abstract: Multiple frequency shift keying (MFSK) is a modulation suitable for transmitting digital data under fading conditions. A quantitative analysis of MFSK-with-diversity is presented. The MFSK ...

Abstract: A 700-MHz Gaussian frequency-shift keying (GFSK) transmitter (Tx) for the Internet of Things (IoT ... To the author’s best knowledge, this is the highest data rate for the GFSK Tx operating ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

This Phase I dose-escalation study in patients with advanced solid tumors was performed to determine the MTD, overall safety, pharmacokinetic (PK) profile and anti-tumor activity of afatinib ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

BriaCell noted that the Bria-IMT regimen has already demonstrated encouraging Phase 2 survival data in a similar patient population and has been granted FDA Fast Track designation for advanced ...

Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling ...